Total Funding
79
95
Total FundingPost-IPO Equity raised
Growth Score
-17 pts
Heat Score
7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
3211
PharmaEssentia develops treatments for myeloproliferative neoplasms, hepatitis, and other diseases.
- Albert Qin: Chief Medical Officer
- Ko-Chung Lin: Founder and Chief Executive OfficerPast Role: Biogen, Head of Adentri Program & Pegylated-Avonex Program
About the Company
PharmaEssentia Corporation is a biopharmaceutical company that develops treatments for myeloproliferative neoplasms, and hepatitis. They deliver biologics for diseases in the areas of hematology and oncology, with products approved in a diversifying pipeline. Their services include biologics, oncology, rare disease, orphan drugs, orphan disease,
drug development, pharmaceuticals, and hematology.
